Symphogen A/S appoints Paul Rohricht as Vice President of Business Development
In his role, Mr. Rohricht will be responsible for worldwide business development for Symphogen's product portfolio consisting of therapeutic symphobodies Sym001 (anti-rhesus D), Sym002 (anti-VIG), Sym 003 (anti-RSV), and Sym004 (anti-cancer). Further he will be instrumental in establishing research collaborations and licensing deals for the company's proprietary technologies.
Rohricht joins Symphogen from Revivicor, Inc., where he was co-founder and Vice President of Corporate Development. In this role he secured financing, negotiated in-licensing of key intellectual property estate, and developed and executed the out-licensing strategy for products developed by the company, and secured several government grants. Prior to Revivicor, Rohricht held the role of Vice President of Business Development at PPL Therapeutics. In addition to licensing, Rohricht has experience in mergers and acquisitions, has started and run his own business development consulting company as well held several other business development and senior sales roles at biotechnology companies throughout his fifteen year career.
Rohricht received his Master's degrees in Science and Engineering and Technology Management/MBA from the University of Pennsylvania (School of Engineering/Wharton School of Business), and his bachelor's degree in biology from St. Olaf College. He has also served in the past as a member of the adjunct faculty at Alvernia College as an instructor in its MBA program, teaching Corporate Finance, Management Finance, Leadership, and International Marketing.
Other news from the department people
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous